Jak3 and the pathogenesis of severe combined immunodeficiency

Molecular Immunology

Volumn 41, Issue 6-7, 2004, Pages 727-737

  O'Shea, John J ^a   Husa, Matthew ^a,b   Li, Denise ^a   Hofmann, Sigrun R ^a   Watford, Wendy ^a   Roberts, Joseph L ^c   Buckley, Rebecca H ^c   Changelian, Paul ^d   Candotti, Fabio ^e  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^e NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CD34 ANTIGEN; CP 690 550; CYCLOSPORIN A; CYTOKINE; IMATINIB; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 4; INTERLEUKIN 7; INTERLEUKIN 7 RECEPTOR; JANUS KINASE; JANUS KINASE 3; POLIOMYELITIS VACCINE; PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; TACROLIMUS; TETANUS TOXOID; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; AMINO ACID SUBSTITUTION; ANEMIA; ANTIBODY RESPONSE; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CELL MATURATION; COMBINED IMMUNODEFICIENCY; CRYSTAL STRUCTURE; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENCY; GENE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC DISORDER; GRAFT REJECTION; GRAFT SURVIVAL; GRANULOCYTOPENIA; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; LIM ONLY DOMAIN 2 GENE; LYMPHOCYTOPENIA; LYMPHOID ORGAN; LYMPHOPROLIFERATIVE DISEASE; METABOLIC DISORDER; MUTATION; NATURAL KILLER CELL; NEPHROTOXICITY; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTO ONCOGENE; RETROVIRUS; REVIEW; T CELL LEUKEMIA; T LYMPHOCYTE; THROMBOCYTOPENIA; VACCINATION; VIRUS INFECTION;

ANIMALIA;

EID: 3042563551     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2004.04.014     Document Type: Article

References (109)

1. Akashi K., Kondo M., von Freeden-Jeffry U., Murray R., Weissman I.L. Bcl-2 rescues T lymphopoiesis in interleukin-7 receptor-deficient mice. Cell. 89:1997;1033-1041
2. Antoine C., Muller S., Cant A., Cavazzana-Calvo M., Veys P., Vossen J., Fasth A., Heilmann C., Wulffraat N., Seger R., Blanche S., Friedrich W., Abinun M., Davies G., Bredius R., Schulz A., Landais P., Fischer A. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet. 361:2003;553-560
3. Argetsinger L.S., Campbell G.S., Yang X., Witthuhn B.A., Silvennoinen O., Ihle J.N., Carter-Su C. Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase. Cell. 74:1993;237-244
4. Asao H., Okuyama C., Kumaki S., Ishii N., Tsuchiya S., Foster D., Sugamura K. Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex. J. Immunol. 167:2001;1-5
5. Bassiri H., Carding S.R. A requirement for IL-2/IL-2 receptor signaling in intrathymic negative selection. J. Immunol. 166:2001;5945-5954
6. Becker T.C., Wherry E.J., Boone D., Murali-Krishna K., Antia R., Ma A., Ahmed R. Interleukin 15 is required for proliferative renewal of virus-specific memory CD8 T cells. J. Exp. Med. 195:2002;1541-1548
7. Boehm T., Foroni L., Kaneko Y., Perutz M.F., Rabbitts T.H. The rhombotin family of cysteine-rich LIM-domain oncogenes: distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13. Proc. Natl. Acad. Sci. USA. 88:1991;4367-4371
8. Boussiotis V.A., Barber D.L., Nakarai T., Freeman G.J., Gribben J.G., Bernstein G.M., D'Andrea A.D., Ritz J., Nadler L.M. Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor. Science. 266:1994;1039-1042
9. Bozzi F., Lefranc G., Villa A., Badolato R., Schumacher R.F., Khalil G., Loiselet J., Bresciani S., O'Shea J.J., Vezzoni P., Notarangelo L.D., Candotti F. Molecular and biochemical characterization of JAK3 deficiency in a patient with severe combined immunodeficiency over 20 years after bone marrow transplantation: implications for treatment. Br. J. Haematol. 102:1998;1363-1366
10. Buckley R.H. Primary immunodeficiency diseases due to defects in lymphocytes. N. Engl. J. Med. 343:2000a;1313-1324
11. Buckley R.H. Primary immunodeficiency diseases due to defects in lymphocytes. N. Engl. J. Med. 343:2000b;1313-1324
12. Buckley R.H., Schiff R.I., Schiff S.E., Markert M.L., Williams L.W., Harville T.O., Roberts J.L., Puck J.M. Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. J. Pediatr. 130:1997;378-387
13. Bunting K.D., Flynn K.J., Riberdy J.M., Doherty P.C., Sorrentino B.P. Virus-specific immunity after gene therapy in a murine model of severe combined immunodeficiency. Proc. Natl. Acad. Sci. USA. 96:1999;232-237
14. Bunting K.D., Lu T., Kelly P.F., Sorrentino B.P. Self-selection by genetically modified committed lymphocyte precursors reverses the phenotype of JAK3-deficient mice without myeloablation. Hum. Gene. Ther. 11:2000;2353-2364
15. Bunting K.D., Sangster M.Y., Ihle J.N., Sorrentino B.P. Restoration of lymphocyte function in Janus kinase 3-deficient mice by retroviral-mediated gene transfer. Nat. Med. 4:1998;58-64
16. Cacalano N.A., Migone T.S., Bazan F., Hanson E.P., Chen M., Candotti F., O'Shea J.J., Johnston J.A. Autosomal SCID caused by a point mutation in the N-terminus of Jak3: mapping of the Jak3-receptor interaction domain. EMBO. J. 18:1999;1549-1558
17. Candeias S., Peschon J.J., Muegge K., Durum S.K. Defective T-cell receptor gamma gene rearrangement in interleukin-7 receptor knockout mice. Immunol. Lett. 57:1997;9-14
18. Candotti F., Johnston J.A., Puck J.M., Sugamura K., O'Shea J.J., Blaese R.M. Retroviral-mediated gene correction for X-linked severe combined immunodeficiency. Blood. 87:1996a;3097-3102
19. Candotti F., Notarangelo L., Visconti R., O'Shea J. Molecular aspects of primary immunodeficiencies: lessons from cytokine and other signaling pathways. J. Clin. Invest. 109:2002;1261-1269
20. Candotti F., O'Shea J.J., Villa A. Severe combined immune deficiencies due to defects of the common gamma chain-JAK3 signaling pathway. Springer Semin. Immunopathol. 19:1998;401-415
21. Candotti F., Oakes S.A., Johnston J.A., Giliani S., Schumacher R.F., Mella P., Fiorini M., Ugazio A.G., Badolato R., Notarangelo L.D., Bozzi F., Macchi P., Strina D., Vezzoni P., Blaese R.M., O'Shea J.J., Villa A. Structural and functional basis for JAK3-deficient severe combined immunodeficiency. Blood. 90:1997;3996-4003
22. Candotti F., Oakes S.A., Johnston J.A., Notarangelo L.D., O'Shea J.J., Blaese R.M. In vitro correction of JAK3-deficient severe combined immunodeficiency by retroviral-mediated gene transduction. J. Exp. Med. 183:1996b;2687-2692
23. Cavazzana-Calvo M., Hacein-Bey S., Yates F., de Villartay J.P., Le Deist F., Fischer A. Gene therapy of severe combined immunodeficiencies. J. Gene. Med. 3:2001;201-206
24. Changelian P.S., Flanagan M.E., Ball D.J., Kent C.R., Magnuson K.S., Martin W.H., Rizzuti B.J., Sawyer P.S., Perry B.D., Brissette W.H., McCurdy S.P., Kudlacz E.M., Conklyn M.J., Elliott E.A., Koslov E.R., Fisher M.B., Strelevitz T.J., Yoon K., Whipple D.A., Sun J., Munchhof M.J., Doty J.L., Casavant J.M., Blumenkopf T.A., Hines M., Brown M.F., Lillie B.M., Subramanyam C., Shang-Poa C., Milici A.J., Beckius G.E., Moyer J.D., Su C., Woodworth T.G., Gaweco A.S., Beals C.R., Littman B.H., Fisher D.A., Smith J.F., Zagouras P., Magna H.A., Saltarelli M.J., Johnson K.S., Nelms L.F., Des Etages S.G., Hayes L.S., Kawabata T.T., Finco-Kent D., Baker D.L., Larson M., Si M.S., Paniagua R., Higgins J., Holm B., Reitz B., Zhou Y.J., Morris R.E., O'Shea J.J., Borie D.C. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science. 302:2003;875-878
25. Chen M., Cheng A., Candotti F., Zhou Y.J., Hymel A., Fasth A., Notarangelo L.D., O'Shea J.J. Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains. Mol. Cell Biol. 20:2000;947-956
26. Chen M., Cheng A., Chen Y.Q., Hymel A., Hanson E.P., Kimmel L., Minami Y., Taniguchi T., Changelian P.S., O'Shea J.J. The amino terminus of JAK3 is necessary and sufficient for binding to the common gamma chain and confers the ability to transmit interleukin 2-mediated signals. Proc. Natl. Acad. Sci. USA. 94:1997;6910-6915
27. Cools J., DeAngelo D.J., Gotlib J., Stover E.H., Legare R.D., Cortes J., Kutok J., Clark J., Galinsky I., Griffin J.D., Cross N.C., Tefferi A., Malone J., Alam R., Schrier S.L., Schmid J., Rose M., Vandenberghe P., Verhoef G., Boogaerts M., Wlodarska I., Kantarjian H., Marynen P., Coutre S.E., Stone R., Gilliland D.G. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348:2003;1201-1214
28. Cooper M.A., Bush J.E., Fehniger T.A., VanDeusen J.B., Waite R.E., Liu Y., Aguila H.L., Caligiuri M.A. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood. 100:2002;3633-3638
29. Darnell J.E. Jr., Kerr I.M., Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 264:1994;1415-1421
30. Druker B.J. Perspectives on the development of a molecularly targeted agent. Cancer Cell. 1:2002;31-36
31. Fehniger T.A., Cooper M.A., Caligiuri M.A. Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev. 13:2002;169-183
32. Firmbach-Kraft I., Byers M., Shows T., Dalla-Favera R., Krolewski J.J. tyk2, prototype of a novel class of non-receptor tyrosine kinase genes. Oncogene. 5:1990;1329-1336
33. Fischer A., Hacein-Bey S., Cavazzana-Calvo M. Gene therapy of severe combined immunodeficiencies. Nat. Rev. Immunol. 2:2002;615-621
34. Frucht D.M., Gadina M., Jagadeesh G.J., Aksentijevich I., Takada K., Bleesing J.J., Nelson J., Muul L.M., Perham G., Morgan G., Gerritsen E.J., Schumacher R.F., Mella P., Veys P.A., Fleisher T.A., Kaminski E.R., Notarangelo L.D., O'Shea J.J., Candotti F. Unexpected and variable phenotypes in a family with JAK3 deficiency. Genes Immun. 2:2001;422-432
35. Fry T.J., Mackall C.L. Interleukin-7: master regulator of peripheral T-cell homeostasis? Trends Immunol. 22:2001;564-571
36. Fry T.J., Mackall C.L. Interleukin-7: from bench to clinic. Blood. 99:2002;3892-3904
37. Goldrath A.W., Sivakumar P.V., Glaccum M., Kennedy M.K., Bevan M.J., Benoist C., Mathis D., Butz E.A. Cytokine requirements for acute and Basal homeostatic proliferation of naive and memory CD8+ T cells. J. Exp. Med. 195:2002;1515-1522
38. Hacein-Bey H., Cavazzana-Calvo M., Le Deist F., Dautry-Varsat A., Hivroz C., Riviere I., Danos O., Heard J.M., Sugamura K., Fischer A., De Saint Basile G. gamma-c gene transfer into SCID X1 patients' B-cell lines restores normal high-affinity interleukin-2 receptor expression and function. Blood. 87:1996;3108-3116
39. Hacein-Bey S., Basile G.D., Lemerle J., Fischer A., Cavazzana-Calvo M. gammac gene transfer in the presence of stem cell factor, FLT-3L, interleukin-7 (IL-7), IL-1, and IL-15 cytokines restores T-cell differentiation from gammac(-) X-linked severe combined immunodeficiency hematopoietic progenitor cells in murine fetal thymic organ cultures. Blood. 92:1998;4090-4097
40. Hacein-Bey-Abina S., Le Deist F., Carlier F., Bouneaud C., Hue C., De Villartay J.P., Thrasher A.J., Wulffraat N., Sorensen R., Dupuis-Girod S., Fischer A., Davies E.G., Kuis W., Leiva L., Cavazzana-Calvo M. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med. 346:2002;1185-1193
41. Haddad E., Landais P., Friedrich W., Gerritsen B., Cavazzana-Calvo M., Morgan G., Bertrand Y., Fasth A., Porta F., Cant A., Espanol T., Muller S., Veys P., Vossen J., Fischer A. Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients. Blood. 91:1998;3646-3653
42. Harpur A.G., Andres A.C., Ziemiecki A., Aston R.R., Wilks A.F. JAK2, a third member of the JAK family of protein tyrosine kinases. Oncogene. 7:1992;1347-1353
43. Johnston J.A., Kawamura M., Kirken R.A., Chen Y.Q., Blake T.B., Shibuya K., Ortaldo J.R., McVicar D.W., O'Shea J.J. Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. Nature. 370:1994;151-153
44. Kawamura M., McVicar D.W., Johnston J.A., Blake T.B., Chen Y.Q., Lal B.K., Lloyd A.R., Kelvin D.J., Staples J.E., Ortaldo J.R., et al. Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes. Proc. Natl. Acad. Sci. USA. 91:1994;6374-6378
45. Khaled A.R., Li W.Q., Huang J., Fry T.J., Khaled A.S., Mackall C.L., Muegge K., Young H.A., Durum S.K. Bax deficiency partially corrects interleukin-7 receptor alpha deficiency. Immunity. 17:2002;561-573
46. Kirken R.A., Erwin R.A., Taub D., Murphy W.J., Behbod F., Wang L., Pericle F., Farrar W.L. Tyrphostin AG-490 inhibits cytokine-mediated JAK3/STAT5a/b signal transduction and cellular proliferation of antigen-activated human T cells. J. Leukoc. Biol. 65:1999;891-899
47. Krolewski J.J., Lee R., Eddy R., Shows T.B., Dalla-Favera R. Identification and chromosomal mapping of new human tyrosine kinase genes. Oncogene. 5:1990;277-282
48. Leonard W.J., Noguchi M., Russell S.M. Sharing of a common gamma chain, by the IL-2, IL-4, and IL-7 receptors: implications for X-linked severe combined immunodeficiency (XSCID). Adv. Exp. Med. Biol. 365:1994;225-232
49. Leonard W.J., O'Shea J.J. Jaks and STATs: biological implications. Annu. Rev. Immunol. 16:1998;293-322
50. Macchi P., Villa A., Giliani S., Sacco M.G., Frattini A., Porta F., Ugazio A.G., Johnston J.A., Candotti F., O'Shea J.J., et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature. 377:1995;65-68
51. Maki K., Sunaga S., Komagata Y., Kodaira Y., Mabuchi A., Karasuyama H., Yokomuro K., Miyazaki J.I., Ikuta K. Interleukin 7 receptor-deficient mice lack gammadelta T cells. Proc. Natl. Acad. Sci. USA. 93:1996;7172-7177
52. Malaviya R., Navara C., Uckun F.M. Role of Janus kinase 3 in mast cell-mediated innate immunity against gram-negative bacteria. Immunity. 15:2001;313-321
53. Malaviya R., Zhu D., Dibirdik I., Uckun F.M. Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis. J. Biol. Chem. 274:1999;27028-27038
54. Malek, T.R., 2003. The main function of IL-2 is to promote the development of T regulatory cells. J. Leukoc. Biol.
55. Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S. The protein kinase complement of the human genome. Science. 298:2002;1912-1934
56. Maraskovsky E., O'Reilly L.A., Teepe M., Corcoran L.M., Peschon J.J., Strasser A. Bcl-2 can rescue T lymphocyte development in interleukin-7 receptor-deficient mice but not in mutant rag-1-/- mice. Cell. 89:1997;1011-1019
57. Mella P., Schumacher R.F., Cranston T., de Saint Basile G., Savoldi G., Notarangelo L.D. Eleven novel JAK3 mutations in patients with severe combined immunodeficiency-including the first patients with mutations in the kinase domain. Hum. Mutat. 18:2001;355-356
58. Meydan N., Grunberger T., Dadi H., Shahar M., Arpaia E., Lapidot Z., Leeder J.S., Freedman M., Cohen A., Gazit A., Levitzki A., Roifman C.M. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature. 379:1996;645-648
59. Migone T.S., Lin J.X., Cereseto A., Mulloy J.C., O'Shea J.J., Franchini G., Leonard W.J. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science. 269:1995;79-81
60. Miyazaki T., Kawahara A., Fujii H., Nakagawa Y., Minami Y., Liu Z.J., Oishi I., Silvennoinen O., Witthuhn B.A., Ihle J.N., et al. Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits. Science. 266:1994;1045-1047
61. Muller M., Briscoe J., Laxton C., Guschin D., Ziemiecki A., Silvennoinen O., Harpur A.G., Barbieri G., Witthuhn B.A., Schindler C., et al. The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction. Nature. 366:1993;129-135
62. Neale G.A., Rehg J.E., Goorha R.M. Disruption of T-cell differentiation precedes T-cell tumor formation in LMO-2 (rhombotin-2) transgenic mice. Leukemia. 11(Suppl 3):1997;289-290
63. Nelson B.H. Interleukin-2 signaling and the maintenance of self-tolerance. Curr. Dir. Autoimmun. 5:2002;92-112
64. Noguchi M., Yi H., Rosenblatt H.M., Filipovich A.H., Adelstein S., Modi W.S., McBride O.W., Leonard W.J. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell. 73:1993;147-157
65. Notarangelo L.D., Giliani S., Mazza C., Mella P., Savoldi G., Rodriguez-Perez C., Mazzolari E., Fiorini M., Duse M., Plebani A., Ugazio A.G., Vihinen M., Candotti F., Schumacher R.F. Of genes and phenotypes: the immunological and molecular spectrum of combined immune deficiency. Defects of the gamma(c)-JAK3 signaling pathway as a model. Immunol. Rev. 178:2000;39-48
66. Notarangelo L.D., Mella P., Jones A., de Saint Basile G., Savoldi G., Cranston T., Vihinen M., Schumacher R.F. Mutations in severe combined immune deficiency (SCID) due to JAK3 deficiency. Hum. Mutat. 18:2001;255-263
67. O'Shea J.J., Gadina M., Schreiber R.D. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell. 109(Suppl):2002;S121-S131
68. Oakes S.A., Candotti F., Johnston J.A., Chen Y.Q., Ryan J.J., Taylor N., Liu X., Hennighausen L., Notarangelo L.D., Paul W.E., Blaese R.M., O'Shea J.J. Signaling via IL-2 and IL-4 in JAK3-deficient severe combined immunodeficiency lymphocytes: JAK3-dependent and independent pathways. Immunity. 5:1996;605-615
69. Otsu M., Anderson S.M., Bodine D.M., Puck J.M., O'Shea J.J., Candotti F. Lymphoid development and function in X-linked severe combined immunodeficiency mice after stem cell gene therapy. Mol. Ther. 1:2000;145-153
70. Ozaki K., Spolski R., Feng C.G., Qi C.F., Cheng J., Sher A., Morse H.C. 3rd, Liu C., Schwartzberg P.L., Leonard W.J. A critical role for IL-21 in regulating immunoglobulin production. Science. 298:2002;1630-1634
71. Parganas E., Wang D., Stravopodis D., Topham D.J., Marine J.C., Teglund S., Vanin E.F., Bodner S., Colamonici O.R., van Deursen J.M., Grosveld G., Ihle J.N. Jak2 is essential for signaling through a variety of cytokine receptors. Cell. 93:1998;385-395
72. Patel D.D., Gooding M.E., Parrott R.E., Curtis K.M., Haynes B.F., Buckley R.H. Thymic function after hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N. Engl. J. Med. 342:2000;1325-1332
73. Perumal N.B., Kenniston T.W. Jr., Tweardy D.J., Dyer K.F., Hoffman R., Peschon J., Appasamy P.M. TCR-gamma genes are rearranged but not transcribed in IL-7R alpha-deficient mice. J. Immunol. 158:1997;5744-5750
74. Peschon J.J., Morrissey P.J., Grabstein K.H., Ramsdell F.J., Maraskovsky E., Gliniak B.C., Park L.S., Ziegler S.F., Williams D.E., Ware C.B., et al. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J. Exp. Med. 180:1994;1955-1960
75. Puck J.M., Deschenes S.M., Porter J.C., Dutra A.S., Brown C.J., Willard H.F., Henthorn P.S. The interleukin-2 receptor gamma chain maps to Xq13.1 and is mutated in X-linked severe combined immunodeficiency, SCIDX1. Hum. Mol. Genet. 2:1993;1099-1104
76. Puck J.M., Pepper A.E., Henthorn P.S., Candotti F., Isakov J., Whitwam T., Conley M.E., Fischer R.E., Rosenblatt H.M., Small T.N., Buckley R.H. Mutation analysis of IL2RG in human X-linked severe combined immunodeficiency. Blood. 89:1997;1968-1977
77. Puel A., Ziegler S.F., Buckley R.H., Leonard W.J. Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat. Genet. 20:1998;394-397
78. Rane S.G., Reddy E.P. JAK3: a novel JAK kinase associated with terminal differentiation of hematopoietic cells. Oncogene. 9:1994;2415-2423
79. Refaeli Y., Van Parijs L., Abbas A.K. Genetic models of abnormal apoptosis in lymphocytes. Immunol. Rev. 169:1999;273-282
80. Roberts, J.L., Lengi, A., Brown, S.M., Chen, M., Zhou, Y.J., O'Shea, J.J., Buckley, R.H., 2003. Janus kinase 3 (JAK3) deficiency: clinical, immunologic, and molecular analyses of 10 patients and outcomes of stem cell transplantation. Blood.
81. Rodig S.J., Meraz M.A., White J.M., Lampe P.A., Riley J.K., Arthur C.D., King K.L., Sheehan K.C., Yin L., Pennica D., Johnson E.M. Jr., Schreiber R.D. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell. 93:1998;373-383
82. Roifman C.M., Zhang J., Chitayat D., Sharfe N. A partial deficiency of interleukin-7R alpha is sufficient to abrogate T-cell development and cause severe combined immunodeficiency. Blood. 96:2000;2803-2807
83. Russell S.M., Johnston J.A., Noguchi M., Kawamura M., Bacon C.M., Friedmann M., Berg M., McVicar D.W., Witthuhn B.A., Silvennoinen O., et al. Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID. Science. 266:1994;1042-1045
84. Russell S.M., Tayebi N., Nakajima H., Riedy M.C., Roberts J.L., Aman M.J., Migone T.S., Noguchi M., Markert M.L., Buckley R.H., et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science. 270:1995;797-800
85. Saemann M.D., Zeyda M., Diakos C., Szekeres A., Bohmig G.A., Kelemen P., Parolini O., Stockinger H., Prieschl E.E., Stulnig T.M., Baumruker T., Zlabinger G.J. Suppression of early T-cell-receptor-triggered cellular activation by the Janus kinase 3 inhibitor WHI-P-154. Transplantation. 75:2003;1864-1872
86. Saharinen P., Takaluoma K., Silvennoinen O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol. Cell Biol. 20:2000;3387-3395
87. Schluns K.S., Kieper W.C., Jameson S.C., Lefrancois L. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat. Immunol. 1:2000;426-432
88. Schluns K.S., Williams K., Ma A., Zheng X.X., Lefrancois L. Cutting edge: requirement for IL-15 in the generation of primary and memory antigen-specific CD8 T cells. J. Immunol. 168:2002;4827-4831
89. Schumacher R.F., Mella P., Badolato R., Fiorini M., Savoldi G., Giliani S., Villa A., Candotti F., Tampal J.J., Notarangelo L.D. Complete genomic organization of the human JAK3 gene and mutation analysis in severe combined immunodeficiency by single-strand conformation polymorphism. Hum. Genet. 106:2000;73-79
90. Seddon B., Tomlinson P., Zamoyska R. Interleukin 7 and T cell receptor signals regulate homeostasis of CD4 memory cells. Nat. Immunol. 4:2003;680-686
91. Shevach E.M. Regulatory T cells in autoimmmunity. Annu. Rev. Immunol. 18:2000;423-449
92. Silvennoinen O., Ihle J.N., Schlessinger J., Levy D.E. Interferon-induced nuclear signalling by Jak protein tyrosine kinases. Nature. 366:1993a;583-585
93. Silvennoinen O., Witthuhn B.A., Quelle F.W., Cleveland J.L., Yi T., Ihle J.N. Structure of the murine Jak2 protein-tyrosine kinase and its role in interleukin 3 signal transduction. Proc. Natl. Acad. Sci. USA. 90:1993b;8429-8433
94. Sorrentino B.P., Lu T., Ihle J., Buckley R.H., Cunningham J.M. A clinical attempt to treat JAK3-deficient SCID using retroviral-mediated gene tranfer to bone marrow CD34+ cells. Mol. Ther. 7:2003;S449
95. Sudbeck E.A., Liu X.P., Narla R.K., Mahajan S., Ghosh S., Mao C., Uckun F.M. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin. Cancer Res. 5:1999;1569-1582
96. Takahashi T., Shirasawa T. Molecular cloning of rat JAK3, a novel member of the JAK family of protein tyrosine kinases. FEBS Lett. 342:1994;124-128
97. Thompson J.E., Cubbon R.M., Cummings R.T., Wicker L.S., Frankshun R., Cunningham B.R., Cameron P.M., Meinke P.T., Liverton N., Weng Y., DeMartino J.A. Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg. Med. Chem. Lett. 12:2002;1219-1223
98. Velazquez L., Fellous M., Stark G.R., Pellegrini S. A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell. 70:1992;313-322
99. Warren A.J., Colledge W.H., Carlton M.B., Evans M.J., Smith A.J., Rabbitts T.H. The oncogenic cysteine-rich LIM domain protein rbtn2 is essential for erythroid development. Cell. 78:1994;45-57
100. Watling D., Guschin D., Muller M., Silvennoinen O., Witthuhn B.A., Quelle F.W., Rogers N.C., Schindler C., Stark G.R., Ihle J.N., et al. Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-gamma signal transduction pathway. Nature. 366:1993;166-170
101. Wilks A.F. Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction. Proc. Natl. Acad. Sci. USA. 86:1989;1603-1607
102. Wilks A.F. Cloning members of protein-tyrosine kinase family using polymerase chain reaction. Methods Enzymol. 200:1991;533-546
103. Wilks A.F., Harpur A.G., Kurban R.R., Ralph S.J., Zurcher G., Ziemiecki A. Two novel protein-tyrosine kinases, each with a second phosphotransferase- related catalytic domain, define a new class of protein kinase. Mol. Cell Biol. 11:1991;2057-2065
104. Witthuhn B.A., Quelle F.W., Silvennoinen O., Yi T., Tang B., Miura O., Ihle J.N. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell. 74:1993;227-236
105. Witthuhn B.A., Silvennoinen O., Miura O., Lai K.S., Cwik C., Liu E.T., Ihle J.N. Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells. Nature. 370:1994;153-157
106. Yamada Y., Warren A.J., Dobson C., Forster A., Pannell R., Rabbitts T.H. The T cell leukemia LIM protein Lmo2 is necessary for adult mouse hematopoiesis. Proc. Natl. Acad. Sci. USA. 95:1998;3890-3895
107. Zhou Y.J., Chen M., Cusack N.A., Kimmel L.H., Magnuson K.S., Boyd J.G., Lin W., Roberts J.L., Lengi A., Buckley R.H., Geahlen R.L., Candotti F., Gadina M., Changelian P.S., O'Shea J.J. Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases. Mol. Cell. 8:2001;959-969
108. Zhou Y.J., Hanson E.P., Chen Y.Q., Magnuson K., Chen M., Swann P.G., Wange R.L., Changelian P.S., O'Shea J.J. Distinct tyrosine phosphorylation sites in JAK3 kinase domain positively and negatively regulate its enzymatic activity. Proc. Natl. Acad. Sci. USA. 94:1997;13850-13855
109. Zhu J., Cote-Sierra J., Guo L., Paul W.E. Stat5 activation plays a critical role in Th2 differentiation. Immunity. 19:2003;739-748